Age-Related Macular Degeneration

Racial and ethnic disparities in ocular comorbidities significantly contributed to US deaths from 2000 to 2019, particularly among American Indian or Alaska Native and Hispanic individuals.

Patients with nAMD and their relatives experience a significant burden due to treatment-related time commitments, but most have no issues traveling to the eye clinic.

An analysis in Denmark projects an equal increase in anti-VEGF injections given to patients with RVO and nAMD, with a minor increase for patients with DME.

An update from Apellis reports 10 confirmed events of retinal vasculitis and 2 suspected events associated with pegcetacoplan injection for geographic atrophy.

Moritz Pettenkofer, MD, presents a case of a 75-year-old male patient with nARMD who has had 53 injections of anti-VEGF therapy over 4 years.

Moritz Pettenkofer, MD, discusses the mechanisms of faricimab and presents a case study of a 66-year-old female with nARMD

Steven D. Schwartz, MD, reviews challenges and unmet needs in treatment of patients with neovascular AMD and DME.

In a recent case series, a substantial percentage of patients with GA experienced "floaters" from presumed intravitreal silicone oil droplets after pegcetacoplan injection.

Application of subretinal bevacizumab and tPA effectively removed subretinal hemorrhage secondary to nAMD, but anti-VEGF treatment must be continued.

The analysis reports clinical characteristics and the GA progression rate in an Asian population differ from those previously reported in White populations.

Mark Barakat, MD, discusses the phase 3 TENAYA and LUCERNE trials for patients with neovascular age-related macular degeneration (nAMD).

Diana Do, MD, provides an overview of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Artificial intelligence use is growing across medicine. From imaging to chatbots, ophthalmology is the center of one of these transformations.

Announced by Iveric Bio, topline results from the phase 3 GATHER2 clinical trial indicate monthly avacincaptad pegol significantly slowed GA growth compared to sham at 24 months.

Patients were treated with fewer anti-VEGF injections in 2020 compared to the previous year, but these changes did not significantly impact BCVA outcomes.

A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.

Faricimab shows improved visual and anatomic outcomes in eyes with nAMD previously treated with aflibercept or brolucizumab.

A posthoc analysis of the phase 3 HAWK and HARRIER trials shows brolucizumab outperforms aflibercept at reducing SHRM thickness in eyes with nAMD.

Results from a cross-sectional analysis of NHANES data found a short sleep duration was associated with an increased risk of early AMD.

New data suggest patients with nAMD on prior anti-VEGF therapy experienced improved visual acuity and macular OCT parameters after switching to faricimab.

Findings from two recent studies provide insight into the association between anti-VEGF treatment for retinal diseases and the risk of kidney injury.

The study evaluated 10-year outcomes of anti-VEGF therapy using a PRN treatment regimen for eyes with neovascular AMD in real-world clinical practice.

Outlook Therapeutics announced receipt of the CRL exactly one year after resubmission of their BLA for ONS-5010 as a treatment for wet age-related macular degeneration, which would have been the first indication for a retinal disease given to an ophthalmic version of bevacizumab.

Experts wrap up their discussion by highlighting key takeaways on the treatment of retinal diseases with anti-vascular endothelial growth factor (Anti-VEGF) therapies.

Experts discuss emerging gene therapies for age-related macular degeneration (AMD) or diabetic macular edema (DME) and key end points considerations.

Apellis Pharmaceuticals identified internal structural variations in the 19-gauge filter needle included in certain injection kits for pegcetacoplan injection, the first FDA-approved treatment for geographic atrophy.

With approval, aflibercept 8 mg becomes the first and only treatment approved in wet AMD and DME for immediate dosing at 8-week and up to 16-week intervals following 3 initial monthly doses.

Initial real-world experience with ranibizumab biosimilar agents revealed no unexpected adverse outcomes across 16 retina centers, with similar efficacy to reference ranibizumab.

Results from the CT-P42 3.1 Study indicate the therapeutic equivalence of the aflibercept biosimilar, CT-P42, to the reference product in eyes with DME.